1. Phase II Study of Amrubicin Combined with Carboplatin for Thymic Carcinoma and Invasive Thymoma: North Japan Lung Cancer Group Study 0803 
Akira Inoue, MD, PhD, Shunichi Sugawara, MD, PhD, Masao Harada, MD, PhD, Kunihiko Kobayashi, MD, PhD, Toshiyuki Kozuki, MD, PhD, Shoichi Kuyama, MD, PhD, Makoto Maemondo, MD, PhD, Hajime Asahina, MD, PhD, Akiko Hisamoto, MD, PhD, Taku Nakagawa, MD, PhD, Katsuyuki Hotta, MD, PhD, Toshihiro Nukiwa, MD, PhD 
Journal of Thoracic Oncology 
Volume 9, Issue 12, Pages (December 2014)
DOI: /JTO
Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

2. FIGURE 1
A, Kaplan–Meier curves for PFS and (B) OS of patients in TC group (blue line) and IT group (red line). Tick marks indicate patients for whom data were censored at the data cutoff point (December 2013). OS, overall survival; PFS, progression-free survival; TC, thymic carcinoma; IT, invasive thymoma.
Journal of Thoracic Oncology 2014 9, DOI: ( /JTO )
Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions